Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum, affecting multiple organ systems if left untreated. According to the World Health Organization (WHO), around 8 million adults aged 15 to 49 years acquired syphilis in 2022. As per the Syphilis Pipeline Analysis by Expert Market Research, ongoing developments in antibiotic therapies, improved diagnostic technologies, and enhanced disease surveillance are driving market growth. The increasing research focus on long-acting formulations, resistance management, and combination therapies is expected to accelerate advancements in the coming years, strengthening global efforts to control and eliminate syphilis.
The Syphilis Drug Pipeline Report by Expert Market Research gives comprehensive insights into syphilis drugs currently undergoing syphilis clinical trials. It covers various aspects related to the details of each of these syphilis drugs under development for Syphilis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The syphilis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from syphilis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing syphilis pipeline development activities. Moreover, syphilis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Syphilis is a bacterial sexually transmitted infection (STI). It can be transmitted via pregnancy and blood transfusion as well. Although curable, it can lead to stillbirths in pregnancy, congenital syphilis in babies and neonatal deaths. Syphilis has three major phases. Primary phase lasts around 21 days and is characterised by the presence of a painless, round sore on the genitals. It may even go unnoticed and heal on its own. Secondary syphilis involves the occurrence of non-itchy rashes on feet, along with greyish lesions on moist areas. Lastly, latent syphilis has no symptoms. However, if left untreated can progress to the final stage after some years. The diagnosis is based on an individual's clinical history, lab tests and physical exams.
Early stages of syphilis are treated with a benzathine penicillin (BPG) injection. It is also approved for pregnant women with syphilis. Antibiotics such as doxycycline, ceftriaxone or azithromycin can be used as a second-line treatment.
This section of the report covers the analysis of syphilis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s syphilis therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The syphilis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for syphilis. There are around 13 drugs in phase IV of syphilis drugs.
The drug molecule categories covered under syphilis pipeline analysis include penicillins, tetracyclines, macrolides, cephalosporins and antibiotics. The treatment alternative depends on the stage of the disease, patient allergies, and multiple factors. Penicillins (administered through injections) remain the first-in-line treatment for various stages of syphilis. For penicillin-intolerant patients, other antibiotics are advised by healthcare providers.
The EMR syphilis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in syphilis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for syphilis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of syphilis drug candidates.
The University of California, Los Angeles is conducting a study to examine an alternative treatment for syphilis infection. As a part of the study, oral cefixime will be administered to adult patients and they will be asked to visit the clinic 2 weeks after treatment initiation. They will undergo laboratory tests to assess ongoing symptoms.
Currently in Phase 2 of a randomized, open-label, non-comparative, adaptive pilot trial, syphilis drug candidate Linezolid is under evaluation for its efficacy as an early syphilis treatment alternative. The participants will be asked to take part in follow-ups at an interval of 1, 3 and 6 months.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Syphilis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for syphilis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into syphilis collaborations, regulatory environments, and potential growth opportunities within syphilis pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share